This study is a randomized, double-blind, multicenter, phase III clinical study to compare the clinical efficacy and safety of HLX10 + chemotherapy+ concurrent radiotherapy vs chemotherapy+ concurrent radiotherapy in subjects with Limited-Stage Small Cell Lung Cancer.
1 Primary · 1 Secondary · Reporting Duration: up to 36 months
482 Total Participants · 2 Treatment Groups
Primary Treatment: HLX10 + carboplatin/cisplatin-etoposide + radiotherapy · Has Placebo Group · Phase 3
Travel, including flights, are covered
Your expenses for travel tickets for this trial will be reimbursed.
Other reimbursement is provided
Other forms of reimbursement are provided for this trial.
Age 18 - No maximum age · All Participants · 14 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: